GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sientra Inc (OTCPK:SIENQ) » Definitions » ROC (Joel Greenblatt) %

Sientra (Sientra) ROC (Joel Greenblatt) % : -253.18% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Sientra ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sientra's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -253.18%.

The historical rank and industry rank for Sientra's ROC (Joel Greenblatt) % or its related term are showing as below:

SIENQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1498.92   Med: -351.37   Max: -28.24
Current: -218.35

During the past 11 years, Sientra's highest ROC (Joel Greenblatt) % was -28.24%. The lowest was -1498.92%. And the median was -351.37%.

SIENQ's ROC (Joel Greenblatt) % is ranked worse than
77.06% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: 0.48 vs SIENQ: -218.35

Sientra's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 34.20% per year.


Sientra ROC (Joel Greenblatt) % Historical Data

The historical data trend for Sientra's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sientra ROC (Joel Greenblatt) % Chart

Sientra Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,498.92 -489.89 -277.76 -194.93 -231.67

Sientra Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -143.24 -296.57 -194.75 -134.68 -253.18

Competitive Comparison of Sientra's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, Sientra's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sientra's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sientra's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Sientra's ROC (Joel Greenblatt) % falls into.



Sientra ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(31.819 + 39.408 + 2.044) - (10.931 + 56.749 + 18.745)
=-13.154

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(29.61 + 39.268 + 2.604) - (11.584 + 59.393 + 20.466)
=-19.961

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Sientra for the quarter that ended in Sep. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-49.624/( ( (20.159 + max(-13.154, 0)) + (19.042 + max(-19.961, 0)) )/ 2 )
=-49.624/( ( 20.159 + 19.042 )/ 2 )
=-49.624/19.6005
=-253.18 %

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sientra  (OTCPK:SIENQ) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Sientra ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Sientra's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sientra (Sientra) Business Description

Traded in Other Exchanges
Address
3333 Michelson Drive, Suite 650, Irvine, CA, USA, 92612
Sientra Inc is a part of the healthcare sector in the United States. Its business involves the provision of silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. Its operating segments are Breast Products and miraDry. The Breast Products segment focuses on sales of breast implants, tissue expanders and scar management products under the brands OPUS, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System and bioTips. Geographically, the firm generates a majority of its revenue from the United States.
Executives
Alexander W. Casdin director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Ronald Menezes director, officer: President and CEO 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Van Hove Caroline F. director 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Oliver Christian Bennett officer: General Counsel and VP 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Irina Erenburg director 420 S. FAIRVIEW AVENUE, SANTA BARBARA CA 93117
Nori Ebersole director C/O UROVANT SCIENCES, INC., 5151 CALIFORNIA AVENUE, SUITE 250, IRVINE CA 92617
Valerie J Miller officer: VP, Controller and Interim CFO
Paul Sean Little officer: Chief Financial Officer SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Jeffrey M Nugent director 1875 SOUTH GRANT STREET, SUITE 110, SAN MATEO CA 94402
Keith J Sullivan director C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Timothy Haines director, 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Philippe Schaison director C/O ACTAVIS PLC MORRIS CORP CENTER III, 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054

Sientra (Sientra) Headlines

From GuruFocus

Q1 2022 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2020 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2019 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2020 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2023 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2019 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024